Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.


TSXV:EVMT - Post by User

Post by PANAGONINVESTon Jun 15, 2016 2:13pm
150 Views
Post# 24968162

Keeping Track of Shareholders' Dilution

Keeping Track of Shareholders' DilutionNews Released on January 25th, 2016.
“It is expected that upon completion of the Consolidation an aggregate of approximately 37,292,743 Common Shares will be issued and outstanding, assuming there are no other changes in the issued capital of Inspira. There is no name change in conjunction with the Consolidation, and Inspira's trading symbol will remain the same”
“In connection with the pace of growth and to further incentivize a growing staff, the board of directors has approved an incentive-based option grant, subject to compliance with applicable securities laws, of 2,170,598 stock options (on a post-Consolidation basis), expiring in 10 years, to certain officers, directors, consultants and employees at an exercise price equal to the close of the Common Shares on the TSX-V on January 27, 2016.”
$0.69 per share was the Closing Price on January 27th, 2016.

News Released on May 31st, 2016.
Terms of the Non-Binding LOI with RBP Healthcare Technologies 
According to the letter of intent, Inspira will acquire the business for total consideration valued at $8.5 million with 6,375,000 shares, representing 75% of the purchase price, valued at $1.00 per share, a more than 20% premium to the net cash and asset backing of Inspira. The remaining 25% of the purchase price will be payable in cash for a total of $2,125,000. Closing of the acquisition will be subject to TSX Venture Exchange ("TSX-V") approval, final due diligence, and a binding purchase agreement which is expected soon. “

News Released on June 9th, 2016
“Under the terms of the definitive purchase agreement, Inspira will acquire all of the stock of RBP Healthcare Technologies for total cash consideration of $2,125,000 and a total of 6,375,000 shares valued at $1.00 per share for total consideration valued at $8,500,000 paid at closing.”
“The Inspira board of directors approved the issuance of 800,000 options to the newly appointed CEO Marc Hecksel and 60,000 options each to Directors Jaime Gerber and Marc Lavine (totaling 120,000 options). The options will have a strike price of $0.51 and will expire on June 8, 2021. Inspira will also issue to arms-length parties 600,000 shares associated with the RBP Healthcare Technologies transaction, included in the total purchase price. The foregoing issuances of shares is subject to TSXV approval."

Shareholders’ Dilution since Consolidation.

Total Shares upon completion = 37,292,743 shares.
Stock options (January 25th, 2016)) = 2,170,598 shares
Acquisition of RBP (May 31st, 2016) = 6,375,000 shares
Stock options (June 9th, 2016) = 920,000 shares
Total dilution so far = 9,465,598 shares to insiders and for acquisition. 25.38% of the Total Shares upon completion of consolidation.

Bullboard Posts